Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Serial novel agents

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Serial novel agents

DEBATE: Follicular lymphoma patient with early progression - Autologous stem cell transplantПодробнее

DEBATE: Follicular lymphoma patient with early progression - Autologous stem cell transplant

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Allogeneic SCTПодробнее

Debate: Hodgkin lymphoma patient who relapses after autologous SCT - Allogeneic SCT

Debate: Relapsed 60 y/o Follicular lymphoma patient after upfront R-CHOP - SCTПодробнее

Debate: Relapsed 60 y/o Follicular lymphoma patient after upfront R-CHOP - SCT

Debate: Young patient with recurrent follicular lymphoma and short remission? - Novel agents/chemoПодробнее

Debate: Young patient with recurrent follicular lymphoma and short remission? - Novel agents/chemo

Real-world analysis of Hodgkin lymphoma outcomes after auto-SCTПодробнее

Real-world analysis of Hodgkin lymphoma outcomes after auto-SCT

DEBATE: Follicular lymphoma patient with early progression - Novel AgentsПодробнее

DEBATE: Follicular lymphoma patient with early progression - Novel Agents

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - SCT-based therapyПодробнее

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - SCT-based therapy

Debate: Relapsed 60 y/o Follicular lymphoma patient after upfront R-CHOP - Novel agentsПодробнее

Debate: Relapsed 60 y/o Follicular lymphoma patient after upfront R-CHOP - Novel agents

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - Radiation therapyПодробнее

Debate: Hodgkin lymphoma patient who remains PET+ at the end of chemotherapy - Radiation therapy

How can we make Hodgkin's disease therapy less toxic and more effective?Подробнее

How can we make Hodgkin's disease therapy less toxic and more effective?

Debate: A Case of Relapsed Peripheral T-Cell Lymphoma - Sequential novel agentsПодробнее

Debate: A Case of Relapsed Peripheral T-Cell Lymphoma - Sequential novel agents

Recurrent follicular lymphoma: Novel approaches vs stem cell transplantПодробнее

Recurrent follicular lymphoma: Novel approaches vs stem cell transplant

Combination therapy for relapsed/refractory Hodgkin lymphoma – results from BV-ICEПодробнее

Combination therapy for relapsed/refractory Hodgkin lymphoma – results from BV-ICE

Debate: Best second line therapy for relapsed Hodgkin lymphoma - Brentuximab alone/+ chemoПодробнее

Debate: Best second line therapy for relapsed Hodgkin lymphoma - Brentuximab alone/+ chemo

Debate: Value to Using Brentuximab vedotin Consolidation early after Auto-SCT in Hodgkin's? - YesПодробнее

Debate: Value to Using Brentuximab vedotin Consolidation early after Auto-SCT in Hodgkin's? - Yes

Debate: Recurrent Hodgkin's lymphoma after ASCT in CR on brentuximab vedotin - AllotransplantПодробнее

Debate: Recurrent Hodgkin's lymphoma after ASCT in CR on brentuximab vedotin - Allotransplant

Debate: Best pre-transplant second line therapy for relapsed Hodgkin lymphoma - Chemo aloneПодробнее

Debate: Best pre-transplant second line therapy for relapsed Hodgkin lymphoma - Chemo alone

Relapsed Hodgkin lymphoma in PET positive patientsПодробнее

Relapsed Hodgkin lymphoma in PET positive patients